These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15156270)

  • 21. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.
    Humbert M; Maître S; Capron F; Rain B; Musset D; Simonneau G
    Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1681-5. PubMed ID: 9603154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
    Conte JV; Gaine SP; Orens JB; Harris T; Rubin LJ
    J Heart Lung Transplant; 1998 Jul; 17(7):679-85. PubMed ID: 9703232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
    N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostacyclins in pulmonary hypertension treatment.
    Pereszlenyi A; Harustiak S; Klepetko W
    Bratisl Lek Listy; 2002; 103(4-5):179-84. PubMed ID: 12413209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradoxical acute thromboembolism during prostacyclin administration.
    Kritz H; Sinzinger H
    Eur Heart J; 1997 Oct; 18(10):1679. PubMed ID: 9347283
    [No Abstract]   [Full Text] [Related]  

  • 26. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension.
    Findlay JY; Plevak DJ; Krowka MJ; Sack EM; Porayko MK
    Liver Transpl Surg; 1999 Sep; 5(5):362-5. PubMed ID: 10477835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
    Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
    Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostacyclin for pulmonary hypertension.
    Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
    Cochrane Database Syst Rev; 2002; (3):CD002994. PubMed ID: 12137667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension.
    Stricker H; Domenighetti G; Fiori G; Mombelli G
    Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACTH deficiency and PGI(2) therapy in chronic thromboembolic pulmonary hypertension.
    Ikari J; Tanabe N; Tatsuno I; Yamanaka M; Sakao S; Tada Y; Kurosu K; Kasahara Y; Takiguchi Y; Tatsumi K
    Int J Cardiol; 2011 Feb; 146(3):449-50. PubMed ID: 21093079
    [No Abstract]   [Full Text] [Related]  

  • 31. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
    Lawhorn S; Lawhorn CD; Davison C
    J Heart Lung Transplant; 1997 Apr; 16(4):472-3. PubMed ID: 9154961
    [No Abstract]   [Full Text] [Related]  

  • 33. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.
    Rafanan AL; Maurer J; Mehta AC; Schilz R
    Chest; 2000 Nov; 118(5):1497-500. PubMed ID: 11083710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery.
    Haché M; Denault A; Bélisle S; Robitaille D; Couture P; Sheridan P; Pellerin M; Babin D; Noël N; Guertin MC; Martineau R; Dupuis J
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):642-9. PubMed ID: 12658208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatments for pulmonary arterial hypertension.
    Liu C; Liu K; Ji Z; Liu G
    Respir Med; 2006 May; 100(5):765-74. PubMed ID: 16549344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epoprostenol treatment of acute pulmonary hypertension is associated with a paradoxical decrease in right ventricular contractility.
    Rex S; Missant C; Segers P; Rossaint R; Wouters PF
    Intensive Care Med; 2008 Jan; 34(1):179-89. PubMed ID: 17710383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension.
    Castelain V; Chemla D; Humbert M; Sitbon O; Simonneau G; Lecarpentier Y; Hervé P
    Am J Respir Crit Care Med; 2002 Feb; 165(3):338-40. PubMed ID: 11818317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
    Gómez Sánchez MA
    Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-coagulation complications in pregnancies with severe pulmonary arterial hypertension.
    Herrero T; Martin E; Poch DS; Roeder HA
    J Matern Fetal Neonatal Med; 2018 May; 31(9):1209-1213. PubMed ID: 28353362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.